FDA’s Pandemic Flu Plan Will Expedite Meetings With Diagnostic Sponsors
This article was originally published in The Gray Sheet
Executive Summary
FDA's "1Pandemic Influenza Preparedness Strategic Plan," released March 14, calls for CDRH to expedite review of applications for new influenza diagnostics
You may also be interested in...
FDA Recommends Additional Warning On Avian Flu Test Labels
An FDA guidance document advises that language be added to labels of tests for detecting influenza A, or avian flu, stating that negative results should be confirmed with a cell culture
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.